Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?

Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease? Inflamm Bowel Dis. 2019 Jul 13;: Authors: Mantaka A, Orfanoudaki E, Koutroubakis IE PMID: 31300823 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31300823?dopt=Abstract

Read More

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease.

Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jul 09;: Authors: Bauman LE, Xiong Y, Mizuno T, Minar P, Fukuda T, Dong M, Rosen MJ, Vinks AA Abstract BACKGROUND: Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. THE OBJECT OF THIS STUDY WAS…

Read More

Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials.

Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post Hoc Analysis of Clinical Trials. Inflamm Bowel Dis. 2019 Jul 02;: Authors: Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK Abstract BACKGROUND: In our clinical practice, women often report excess weight gain with infliximab (IFX) use. There are currently no studies investigating weight gain after antitumor necrosis factor therapy in patients with inflammatory bowel disease. The objective of this study was to evaluate the association of clinical factors, with a particular focus on…

Read More

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Jun 27;: Authors: Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R Abstract BACKGROUND: Increasing evidence supports the use of reactive therapeutic drug monitoring (TDM) in Crohn’s disease (CD) and ulcerative colitis (UC) following secondary loss of response. It is still unknown if proactive TDM can improve clinical outcomes. METHODS: Consecutive patients completing infliximab (IFX) induction therapy were prospectively allocated into a…

Read More

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial.

Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut. 2019 Feb 01;: Authors: de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D’Haens GR, Bemelman WA, Ponsioen CY, LIR!C study group Abstract OBJECTIVE: Evaluate the cost-effectiveness of laparoscopic ileocaecal resection compared with infliximab in patients with ileocaecal Crohn’s disease failing conventional therapy. DESIGN: A multicentre randomised controlled trial was performed in 29 centres in The Netherlands and the…

Read More

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort.

Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2019 Jun 10;: Authors: Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP Abstract BACKGROUND: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn’s disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of…

Read More

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease.

Related Articles Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease. Clin Gastroenterol Hepatol. 2019 May 22;: Authors: Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D’Haens G, Vermeire S, Gils A Abstract BACKGROUND AND AIMS: In the TAILORIX trial, no benefit could be shown of infliximab dose escalation based on pharmacokinetic (infliximab serum concentrations) and pharmacodynamic (biomarkers and symptoms) monitoring compared to dose escalation based…

Read More
<< Go Back